School of Medicine, Medical Science Building, Room D204, Tsinghua University, Beijing, 100084, China.
School of Life Sciences, Tsinghua University, Beijing, China.
Sci Rep. 2022 Apr 5;12(1):5672. doi: 10.1038/s41598-022-07746-8.
C9ORF72 GGGGCC repeat expansion is the most common genetic cause for amyotrophic lateral sclerosis and frontotemporal dementia, which generates abnormal DNA and RNA structures and produces toxic proteins. Recently, efficacy of CRISPR/Cas9-mediated editing has been proven in treatment of disease. However, DNA low complexity surrounding C9ORF72 expansion increases the off-target risks. Here we provide a dual-gRNA design outside of the low complexity region which enables us to remove the repeat DNA in a 'cutting-deletion-fusion' manner with a high fusion efficiency (50%). Our dual-gRNA design limits off-target effect and does not significantly affect C9ORF72 expression. In neurons carrying patient C9ORF72 expansion, our approach removes the repeat DNA and corrects the RNA foci in vitro and in vivo. Therefore, we conclude that our proof-of-concept design correct C9ORF72 repeat expansion, which may have potential therapeutic value for the patients.
C9ORF72 GGGGCC 重复扩展是肌萎缩侧索硬化症和额颞叶痴呆的最常见遗传原因,它会产生异常的 DNA 和 RNA 结构,并产生毒性蛋白。最近,CRISPR/Cas9 介导的编辑在疾病治疗中的疗效已得到证实。然而,C9ORF72 扩展周围的 DNA 低复杂度会增加脱靶风险。在这里,我们在低复杂度区域之外提供了一种双 gRNA 设计,使我们能够以高融合效率(50%)以“切割-缺失-融合”的方式去除重复 DNA。我们的双 gRNA 设计限制了脱靶效应,并且不会显著影响 C9ORF72 的表达。在携带患者 C9ORF72 扩展的神经元中,我们的方法在体外和体内去除重复 DNA 并纠正 RNA 焦点。因此,我们得出结论,我们的概念验证设计纠正了 C9ORF72 重复扩展,这可能对患者具有潜在的治疗价值。